Immunomodulatory effects of poly(I,C)-LC in cancer patients.
Poly(I,C)-LC was administered in low (1 mg/m2) and intermediate (4 mg/m2) doses to cancer patients by intramuscular injection or intravenous infusion to evaluate the immunomodulatory effects. Natural killer cell (NK) activity was elevated slightly at the low dose and remained unchanged overall, but some depression was observed at the 4 mg/m2 intravenous dose. Monocyte function was elevated in all groups of patients, as was the interferon-induced enzyme 2'5'-oligo-A synthetase. These increases were observed at the 1 mg/m2 intramuscular dose, despite a lack of detectable circulating serum interferon (IFN). In regard to cell surface markers, poly(I,C)-LC induced an increase in OKT10-positive cells and a small but consistent trend toward increases in the ratio of Leu-3/Leu-2-positive cells. Lymphocyte proliferation in response to concanavalin A was depressed by poly(I,C)-LC administration. Although an optimum immunomodulatory dose and schedule was not determined, the data indicate that low doses produce significant changes in immune function and that induction of detectable levels of circulating interferon is not required for poly(I,C)-LC to have biological effects.
D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood; D000276:Adjuvants, Immunologic; D002266:Carboxymethylcellulose Sodium / Q000008:administration & dosage / Q000627:therapeutic use* / Q000031:analogs & derivatives; D004341:Drug Evaluation; D006801:Humans; D066298:In Vitro Techniques; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D007962:Leukocytes / Q000145:classification / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008747:Methylcellulose / Q000031:analogs & derivatives*; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D011070:Poly I-C / Q000008:administration & dosage / Q000627:therapeutic use*; D011107:Polylysine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000031:analogs & derivatives
D000276:Adjuvants, Immunologic; D011107:Polylysine; C019531:poly ICLC; D008747:Methylcellulose; D015088:2',5'-Oligoadenylate Synthetase; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C